Literature DB >> 33162849

Consequences of Recurrence of Major Depressive Disorder: Is Stopping Effective Antidepressant Medications Ever Safe?

Jennifer Severe1, John F Greden1, Priyanka Reddy1.   

Abstract

According to the World Health Organization, major depressive disorder is the world's leading cause of disability. If clinical remission is not attained and sustained, episodes tend to recur with greater severity and with lessening responsivity to conventional treatments. Reasonably well-established clues and guidelines are presented about the high risk and profound consequences of recurrence of major depressive disorder if successful antidepressant treatments are discontinued. The authors describe actions required to achieve a "lifetime wellness" focus for treatment. Current approaches would need to be transformed from attainment of clinical remission to attainment and maintenance of lifetime wellness, with the knowledge that some individuals may need continuous treatment. Risk factors would need to be assessed and used to formulate clinical treatment guidelines for risk of recurrence. Clinical trials would need to be greatly lengthened. Measurement-based care and precision medicine would be the foundation for informing clinical decisions. The authors provide guidance in determining how to discontinue antidepressants if that decision is made despite risks.
Copyright © by the American Psychiatric Association.

Entities:  

Keywords:  Antidepressants; Major depressive disorder

Year:  2020        PMID: 33162849      PMCID: PMC7587881          DOI: 10.1176/appi.focus.20200008

Source DB:  PubMed          Journal:  Focus (Am Psychiatr Publ)        ISSN: 1541-4094


  53 in total

1.  Mobile apps for mood tracking: an analysis of features and user reviews.

Authors:  Clara Caldeira; Yu Chen; Lesley Chan; Vivian Pham; Yunan Chen; Kai Zheng
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

2.  Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study.

Authors:  John F Greden; Sagar V Parikh; Anthony J Rothschild; Michael E Thase; Boadie W Dunlop; Charles DeBattista; Charles R Conway; Brent P Forester; Francis M Mondimore; Richard C Shelton; Matthew Macaluso; James Li; Krystal Brown; Alexa Gilbert; Lindsey Burns; Michael R Jablonski; Bryan Dechairo
Journal:  J Psychiatr Res       Date:  2019-01-04       Impact factor: 4.791

Review 3.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.

Authors:  Sidney H Kennedy; Raymond W Lam; Roger S McIntyre; S Valérie Tourjman; Venkat Bhat; Pierre Blier; Mehrul Hasnain; Fabrice Jollant; Anthony J Levitt; Glenda M MacQueen; Shane J McInerney; Diane McIntosh; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Norma L Pearson; Arun V Ravindran; Rudolf Uher
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

Review 4.  The neurobiology of depression.

Authors:  Eleni Palazidou
Journal:  Br Med Bull       Date:  2012-02-14       Impact factor: 4.291

5.  Predictors of long-term prognosis of depression.

Authors:  Ian Colman; Kiyuri Naicker; Yiye Zeng; Anushka Ataullahjan; Ambikaipakan Senthilselvan; Scott B Patten
Journal:  CMAJ       Date:  2011-10-24       Impact factor: 8.262

6.  The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.

Authors:  Martin B Keller; Madhukar H Trivedi; Michael E Thase; Richard C Shelton; Susan G Kornstein; Charles B Nemeroff; Edward S Friedman; Alan J Gelenberg; James H Kocsis; David L Dunner; Boadie W Dunlop; Robert M Hirschfeld; Anthony J Rothschild; James M Ferguson; Alan F Schatzberg; John M Zajecka; Ron Pedersen; Bing Yan; Saeeduddin Ahmed; Michael Schmidt; Philip T Ninan
Journal:  Biol Psychiatry       Date:  2007-09-07       Impact factor: 13.382

7.  Severity classification on the Hamilton Depression Rating Scale.

Authors:  Mark Zimmerman; Jennifer H Martinez; Diane Young; Iwona Chelminski; Kristy Dalrymple
Journal:  J Affect Disord       Date:  2013-06-04       Impact factor: 4.839

8.  Five-year outcome for maintenance therapies in recurrent depression.

Authors:  D J Kupfer; E Frank; J M Perel; C Cornes; A G Mallinger; M E Thase; A B McEachran; V J Grochocinski
Journal:  Arch Gen Psychiatry       Date:  1992-10

9.  Helping patients with depression achieve wellness.

Authors:  Mark Hyman Rapaport
Journal:  J Clin Psychiatry       Date:  2009-05       Impact factor: 4.384

10.  Development and validation of risk prediction algorithms to estimate future risk of common cancers in men and women: prospective cohort study.

Authors:  Julia Hippisley-Cox; Carol Coupland
Journal:  BMJ Open       Date:  2015-03-17       Impact factor: 2.692

View more
  3 in total

1.  NNDC Special Issue: Challenges of Mood Disorders Care.

Authors:  John F Greden; J Raymond DePaulo
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-04-23

2.  All-Solid-State Potentiometric Platforms Modified with a Multi-Walled Carbon Nanotubes for Fluoxetine Determination.

Authors:  Hisham S M Abd-Rabboh; Heba M Hashem; Layla M S Al Shagri; Abdel El-Galil E Amr; Abdulrahman A Almehizia; Ahmed M Naglah; Ayman H Kamel
Journal:  Membranes (Basel)       Date:  2022-04-21

3.  Development and validation of an automated solid-phase extraction-LC-MS/MS method for the bioanalysis of fluoxetine in human plasma.

Authors:  Ishtiaque Ahmad; Zabih Ullah; Mohd Ibrahim Khan; Abdullah Khaloofa Alahmari; Mohd Faiyaz Khan
Journal:  J Adv Pharm Technol Res       Date:  2021-07-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.